Please fill out the form below to receive OSUCCC – James publications.

* Required Fields

Personal Information
Contact Information

View our Terms of Use.


Frontiers magazine describes advances in cancer research and clinical care at the OSUCCC – James. Each issue typically includes three feature stories, a commentary about a topical issue of interest to oncologists and information about developments within Ohio State’s cancer program. Frontiers is published three times a year, along with a special issue devoted to research supported by Pelotonia, an annual grassroots bicycle tour that raises money for cancer research at the OSUCCC – James.

ImpactCancer magazine shares the stories of the generous supporters of the OSUCCC – James and the impact their gifts have on our patients, research and clinical care. Published three times each year, impactCancer's aim is to uplift and encourage all those supporting the OSUCCC – James vision of a cancer-free world. This also includes a monthly e-newsletter.

The OSUCCC – James is working to create a cancer-free world by integrating personalized patient care, excellence in education and groundbreaking research. We invite you to read about some of our recent achievements and activities.

This investment report summarizes how Pelotonia funds have been distributed. It also shows how the money benefits such key areas as: our Intramural Research Program for teams of faculty scientists; our Fellowship Program for students doing cancer research with faculty mentors; the purchase of new equipment for cancer research; support for our newly recruited scientists; some large-scale strategic investments; and our statewide initiatives to improve cancer prevention and care around Ohio.

Oncology Update is a bimonthly e-newsletter for public and cancer industry peer audiences that chronicles research and clinical advancements—as well as new grants, recruits, publications, awards/honors, upcoming events and employment opportunities—at the OSUCCC – James.

Get monthly email updates on open cancer clinical trials at The Ohio State University.